Lyell Immunopharma Newsroom

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Zacks Dec 13 21:40

Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma

BarchartDec 10 20:26

Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024

BenzingaDec 10 14:58

Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA

BreakingsDec 10 10:01

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

GlobeNewswireDec 10 10:00

Express News | Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

BreakingsDec 10 10:00

Express News | Lyell Immunopharma Files Prospectus Related to Resale From Time to Time by Selling Stockholders of up to 37.5 Mln Shares of Common Stock - SEC Filing

BreakingsNov 30 05:21

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

BenzingaNov 12 20:00

HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

BenzingaNov 12 19:45 · Ratings

Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges

TipRanksNov 12 19:16 · Ratings

Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year

Simply Wall StNov 10 21:09

Lyell Immunopharma: Q3 Earnings Snapshot

Yahoo FinanceNov 8 06:22

Lyell Immunopharma 3Q Loss/Shr $44.6M >LYEL

Dow JonesNov 8 05:36

Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report

SECNov 8 05:26 · Announcements

Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $34,000

MT NewswiresNov 8 05:19

Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

SECNov 8 05:14

Express News | Lyell Immunopharma Q3 Operating Income USD -50.505 Million

BreakingsNov 8 05:05

Express News | Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

BreakingsNov 8 05:05

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Dow JonesNov 8 05:05

Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.

BenzingaNov 7 01:07